Literature DB >> 19967773

Complications and risk factors of infection in pediatric hemato-oncology patients with totally implantable access ports (TIAPs).

So-Hyun Nam1, Dae-Yeon Kim, Seong-Chul Kim, In-Koo Kim.   

Abstract

BACKGROUND: Totally implantable access ports (TIAPs) are widely used in pediatric hematology-oncology patients. We investigated the incidence of complications, causes of TIAP removal, and risk factors for infection. PROCEDURE: We retrospectively analyzed the clinical, demographic, and surgical characteristics in 225 pediatric hematology-oncology patients implanted with 238 TIAPs between January 2004 and December 2005.
RESULTS: Except for 20 patients lost to follow-up, the mean maintenance period was 724.8 +/- 500.6 days (range: 17-2,124). Mechanical complications occurred in seven patients (2.9%). The causes of TIAP removal were termination of use in 130 patients (59.6%), death from primary disease with TIAP in situ in 35 (14.7%), infection in 35 (14.7%), and obstruction in 4 (1.8%). Early infections occurred in nine patients at mean 37.77 +/- 16.44 days (range: 17-56). Late infections occurred in 26 patients at mean 334.5 +/- 257.82 days (range: 68-997). Univariate analysis showed that the risk factors of early infection were re-implantation (P = 0.022) and long operation time (P = 0.045). The risk factors of late infection were ANC <500/mm(3) (P = 0.011) and platelet count <50,000/mm(3) (P < 0.001). In multivariate analysis, re-implantation was a significant risk factor of early infection (P = 0.033, OR 4.528) and low platelet count (<50,000/mm(3)) was the independent risk factor for late infection (P = 0.005, OR 4.24).
CONCLUSIONS: Correct procedure and careful use decreases the incidence of early infection and leads to the prevention of re-implantation. Initial thrombocytopenia was attributable to bone marrow suppression caused by hematologic malignancies or severe infection. Thus, this condition is of value in predicting late infection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19967773     DOI: 10.1002/pbc.22286

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  7 in total

Review 1.  Catheter-related infections in pediatric patients with cancer.

Authors:  V Cecinati; L Brescia; L Tagliaferri; P Giordano; S Esposito
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-06-03       Impact factor: 3.267

2.  Study of feasibility and acceptability of subcutaneous implantable ports (SIPs) in cancer patients.

Authors:  Lalit Mittal; Manas Kalra; Amita Mahajan
Journal:  Indian J Pediatr       Date:  2012-02-29       Impact factor: 1.967

3.  Catheter-related bloodstream infection with removal of catheter in pediatric oncology patients: a 10-year experience in Taiwan.

Authors:  Shih-Hsiang Chen; Chao-Ping Yang; Tang-Her Jaing; Jin-Yao Lai; Iou-Jih Hung
Journal:  Int J Clin Oncol       Date:  2011-06-18       Impact factor: 3.402

4.  Thrombosis as a complication of central venous access in pediatric patients with malignancies: a 5-year single-center experience.

Authors:  Verena Wiegering; Sophie Schmid; Oliver Andres; Clemens Wirth; Armin Wiegering; Thomas Meyer; Beate Winkler; Paul G Schlegel; Matthias Eyrich
Journal:  BMC Hematol       Date:  2014-10-01

5.  Late complications of totally implantable venous access ports in patients with cancer: Risk factors and related nursing strategies.

Authors:  Xin-Yan Yu; Jia-Lan Xu; Dan Li; Zi-Fang Jiang
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

6.  Incidence and Risk Factors for Totally Implantable Venous Access Device Infections in Pediatric Patients With Cancer: A Study of 25,954 Device-Days.

Authors:  Joon Kee Lee; Young Bae Choi
Journal:  J Korean Med Sci       Date:  2022-09-05       Impact factor: 5.354

7.  Comparison of 2% Chlorhexidine Gluconate in 70% Alcohol and 10% Povidone-Iodine Used for Port Catheter Dressing Changes in Pediatric Hematology-Oncology Patients: A Prospective Observational Study.

Authors:  Elif Bakır; Tufan Aslı Sezer; Hicran Çavuşoğlu; Aslınur Özkaya Parlakay; Orhan Gürsel
Journal:  Turk Arch Pediatr       Date:  2021-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.